Evidence map›Paper›PMID 42905375›Full record

ArticleBreast cancer (Tokyo, Japan)2026

A phase II study combining radiotherapy and atezolizumab/nab-paclitaxel for inoperable or recurrent programmed death-ligand 1-positive triple-negative breast cancer: IMRad-Br study protocol and safety run-in.

Hiroshi Ishiguro, Nobuhiro Hoshi, Shin-Ei Noda, Emi Tokuda, Asami Nukui, Yuya Yoshimoto, Fumiaki Takahashi, Shigehira Saji, Shingo Kato, Tohru Ohtake and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hiroshi IshiguroDepartment of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Nobuhiro HoshiDepartment of Breast Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Shin-Ei NodaDepartment of Radiation Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Emi TokudaDepartment of Medical Oncology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Asami NukuiDepartment of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Yuya YoshimotoDepartment of Radiation Oncology, School of Medicine, Fukushima Medical University, 1 Hikariga-Oka, Fukushima City, Fukushima, 960-1295, Japan.
Fumiaki TakahashiDepartment of Information Science, Iwate Medical University, Yahaba, Japan.
Shigehira SajiDepartment of Medical Oncology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Shingo KatoDepartment of Radiation Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Tohru OhtakeDepartment of Breast Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Akihiko OsakiDepartment of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Yoshiyuki SuzukiDepartment of Radiation Oncology, School of Medicine, Fukushima Medical University, 1 Hikariga-Oka, Fukushima City, Fukushima, 960-1295, Japan. ysuzu@fmu.ac.jp.ORCID http://orcid.org/0000-0001-8786-9080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expressions, with poor prognosis and limited treatment options. Studies have demonstrated the efficacy of immune checkpoint inhibitors (ICIs) combined with chemotherapy in patients with programmed death-ligand 1 (PD-L1)-positive advanced TNBC. Radiotherapy (RT) may enhance therapeutic effects when combined with ICIs.

methodsIn this ongoing single-arm, multicenter phase II trial (IMRad-Br; jRCTs021210010), we aimed to evaluate the safety and feasibility of combining atezolizumab/nab-paclitaxel with local RT in patients with inoperable or recurrent PD-L1-positive TNBC. Patients received atezolizumab (840 mg on days 1 and 15 of a 28-day cycle) and nab-paclitaxel (100 mg/m

resultsAmong the seven patients enrolled, one PAEI was observed (grade 4 liver injury), which improved with treatment interruption and follow-up. Two additional serious adverse events occurred but were unrelated to the study treatment. No unexpected toxicity was observed. Combination therapy was deemed feasible by an Independent Data Monitoring Committee.

conclusionThe combination of atezolizumab/nab-paclitaxel with local RT was feasible and did not result in unexpected toxicities during the safety run-in phase. This study is ongoing to evaluate the safety and therapeutic potential of ICI-RT combination therapy for recurrent PD-L1-positive TNBC. The final analysis will determine whether this approach merits broader clinical adoption.

Indexed as

AtezolizumabImmune checkpoint inhibitorsNab-paclitaxelRadiotherapyTriple-negative breast cancer

Identifiers

PMID42905375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.